The Effect of Teprotumumab on Thyroid Eye Disease and Thyroid Dysfunction
This protocol studies the clinical outcome of patients with active thyroid disease with visually significant signs and symptoms of proptosis, pain, diplopiam lid/orbital edema, or lid/orbital erythema recommended for treatment with teprotumumab infusion (Tepezza®). Patients recommended for treatment will be evaluated by an oculoplastic surgeon (Dr. Eva Chou) and endocrinologist (Dr. Thanh Hoang).
- EligibilityCriteria: Inclusion Criteria:  only DOD beneficiaries adult patients 18 years of age or older adult patients with proptosis, ocular/orbital pain, diplopia, lid/orbital edema, or lid/orbital erythema associated with autoimmune thyroid disease  Exclusion Criteria:  Patients with evidence of compressive optic neuropathy necessitating urgent orbital decompression or external beam radiation patients with a history of uncontrolled diabetes mellitus patients with a history/diagnosis of uncontrolled inflammatory bowel disease patients under age 18 years patients who are pregnant or trying to become pregnant. - HealthyVolunteers: Accepts Healthy Volunteers - Gender: All - MinimumAge: 18 Years - StdAgeList: Adult, Older Adult - StudyPopulation: The study participants were 18-80 years old at the time of treatment with teprotumumab, diagnosed with autoimmune thyroid disease (positive stimulating thyroid receptor antibodies or elevated TSI), presenting with active eye disease (associated with at least one of the following: lid retraction of ≥2 mm, moderate or severe soft-tissue involvement, proptosis of ≥3 mm above the normal values for race and sex, and periodic or constant diplopia), and treated with at least one dose of teprotumumab. - SamplingMethod: Probability Sample